Evidence map›Paper›PMID 39696540›Full record

ArticleGenome medicine2024

Spatial transcriptome profiling identifies DTX3L and BST2 as key biomarkers in esophageal squamous cell carcinoma tumorigenesis.

Rutao Li, Na Li, Qianqian Yang, Xing Tong, Wei Wang, Chang Li, Jun Zhao, Dong Jiang, Haitao Huang, Chen Fang and 12 more

Abstract read
In one paragraph

Article in Genome medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Mast cell driven immunometabolism as a therapeutic entry point in ESCC.Frontiers in cell and developmental biology · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rutao Li *Department of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Na Li *Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China. lina574359748@gmail.com.
Qianqian Yang *Department of Pathology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Xing Tong *Department of Pathology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Wei Wang *Shenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
Chang LiDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Jun ZhaoDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Dong JiangDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Haitao HuangDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Chen FangDepartment of Thoracic Surgery, the Fourth Affiliated Hospital Affiliated to Soochow University, Suzhou, 215000, China.
Kai XieDepartment of Thoracic Surgery, the Fourth Affiliated Hospital Affiliated to Soochow University, Suzhou, 215000, China.
Jiamin YuanDepartment of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Shaomu ChenDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Guangbin LiDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Haitao LuoShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
Zhibo GaoShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
Dongfang WuShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
Xiaoli CuiShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, YuceBio Technology Co., Ltd, Shenzhen, 518000, China.
Wei JiangDepartment of Thoracic Surgery, the Fourth Affiliated Hospital Affiliated to Soochow University, Suzhou, 215000, China.
Lingchuan GuoDepartment of Pathology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China. szglc@hotmail.com.
Haitao MaDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China. mht7403@163.com.
Yu FengDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China. fengyu1@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnderstanding the stepwise progression of esophageal squamous cell carcinoma (ESCC) is crucial for developing customized strategies for early detection and optimal clinical management. Herein, we aimed to unravel the transcriptional and immunologic alterations occurring during malignant transformation and identify clinically significant biomarkers of ESCC.

methodsDigital spatial profiling (DSP) was performed on 11 patients with early-stage ESCC (pT1) to explore the transcriptional alterations in epithelial, immune cell, and non-immune cell stromal compartments across regions of distinct histology, including normal tissues, low- and high-grade dysplasia, and cancerous tissues. Furthermore, single-cell spatial transcriptomics was performed using the CosMx Spatial Molecular Imaging (SMI) system on 4 additional patients with pT1 ESCC. Immunohistochemical (IHC) analysis was performed on consecutive histological sections of 20 pT1 ESCCs. Additionally, public bulk and single-cell RNA-sequencing (scRNA-seq) datasets were analyzed, and in vitro and in vivo functional studies were conducted.

resultsSpatial transcriptional reprogramming and dynamic cell signaling pathways that determined ESCC progression were delineated. Increased infiltration of macrophages from normal tissues through dysplasia to cancerous tissues occurred. Macrophage subtypes were characterized using the scRNA-seq dataset. Cell-cell communication analysis of scRNA-seq and SMI data indicated that the migration inhibitory factor (MIF)-CD74 axis may exhibit pro-tumor interactions between macrophages and epithelial cells. DSP, SMI, and IHC data demonstrated that DTX3L expression in epithelial cells and BST2 expression in stromal cells increased gradually with ESCC progression. Functional studies demonstrated that DTX3L or BST2 knockdown inhibited ESCC proliferation and migration and decreased M2 polarization of tumor-associated macrophages.

conclusionsSpatial profiling comprehensively characterized the molecular and immunological hallmarks from normal tissue to ESCC, guiding the way to a deeper understanding of the tumorigenesis and progression of this disease and contributing to the prevention of ESCC. Within this exploration, we uncovered biomarkers that exhibit a robust correlation with ESCC progression, offering potential new avenues for insightful therapeutic approaches.

Indexed as

Biomarkers, TumorEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGene Expression ProfilingGene Expression Regulation, NeoplasticGPI-Linked ProteinsAnimalsAntigens, CDBone Marrow Stromal Antigen 2CarcinogenesisCell Line, TumorFemaleHumansMacrophagesMaleMiceAntigens, CDBiomarkers, TumorBone Marrow Stromal Antigen 2BST2 protein, humanGPI-Linked ProteinsEsophageal squamous cell carcinomaFunctional studiesPolarizationSingle-cell transcriptomeSpatial biomarkerSpatial transcriptomeTumor-associated macrophageTumorigenesis

Identifiers

PMID39696540
PMCPMC11657267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.